Pfizer Inc. (NYSE:PFE) Shares Acquired by Chapin Davis Inc.

Chapin Davis Inc. boosted its stake in Pfizer Inc. (NYSE:PFE) by 2.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,981 shares of the biopharmaceutical company’s stock after acquiring an additional 1,627 shares during the period. Chapin Davis Inc.’s holdings in Pfizer were worth $1,736,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Olistico Wealth LLC acquired a new position in Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Quarry LP acquired a new stake in shares of Pfizer in the second quarter valued at about $31,000. Creekmur Asset Management LLC purchased a new stake in Pfizer during the fourth quarter worth about $32,000. Finally, Trivant Custom Portfolio Group LLC grew its position in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock opened at $29.19 on Tuesday. The firm has a 50 day moving average of $29.17 and a two-hundred day moving average of $28.32. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $33.92. The company has a market capitalization of $165.41 billion, a price-to-earnings ratio of -486.50, a P/E/G ratio of 1.23 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the company earned $0.67 EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Thursday, October 3rd. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Finally, Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.